Anti-inflammatory therapy with nebulised dornase alfa for severe COVID-19 pneumonia
Joanna C. Porter, Jamie Inshaw, Vincente Joel Solis, Emma Denneny, Rebecca Evans, Mia I. Temkin, Nathalia De Vasconcelos, Iker Valle Aramburu, Dennis Hoving, Donna Basire, Tracey Crissell, Jesusa Guinto, Alison Webb, Hanif Esmail, Victoria Johnston, Anna Last, Thomas Rampling, Elisa Theresa Helbig, Lena Lippert, Florian Kurth, Bryan Williams, Aiden Flynn, Pauline T Lukey, Veronique Birault, View ORCID ProfileVenizelos Papayannopoulos
doi: https://doi.org/10.1101/2022.04.14.22272888
Joanna C. Porter
1UCL Respiratory, University College London, UK
2University College London Hospitals NHS Trust, London, UK
Jamie Inshaw
3Exploristics, Belfast, N. Ireland
Vincente Joel Solis
2University College London Hospitals NHS Trust, London, UK
Emma Denneny
1UCL Respiratory, University College London, UK
2University College London Hospitals NHS Trust, London, UK
Rebecca Evans
2University College London Hospitals NHS Trust, London, UK
Mia I. Temkin
4Antimicrobial Defence lab, The Francis Crick Institute, London, UK
Nathalia De Vasconcelos
4Antimicrobial Defence lab, The Francis Crick Institute, London, UK
Iker Valle Aramburu
4Antimicrobial Defence lab, The Francis Crick Institute, London, UK
Dennis Hoving
4Antimicrobial Defence lab, The Francis Crick Institute, London, UK
Donna Basire
1UCL Respiratory, University College London, UK
Tracey Crissell
2University College London Hospitals NHS Trust, London, UK
Jesusa Guinto
2University College London Hospitals NHS Trust, London, UK
Alison Webb
2University College London Hospitals NHS Trust, London, UK
Hanif Esmail
2University College London Hospitals NHS Trust, London, UK
5National Institute for Health Research, University College London Hospital Biomedical Research Centre, UK
Victoria Johnston
2University College London Hospitals NHS Trust, London, UK
5National Institute for Health Research, University College London Hospital Biomedical Research Centre, UK
Anna Last
2University College London Hospitals NHS Trust, London, UK
6Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK
Thomas Rampling
2University College London Hospitals NHS Trust, London, UK
5National Institute for Health Research, University College London Hospital Biomedical Research Centre, UK
Elisa Theresa Helbig
7Charité – Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany
Lena Lippert
7Charité – Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany
Florian Kurth
7Charité – Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany
Bryan Williams
2University College London Hospitals NHS Trust, London, UK
5National Institute for Health Research, University College London Hospital Biomedical Research Centre, UK
Aiden Flynn
3Exploristics, Belfast, N. Ireland
Pauline T Lukey
8Target to Treatment Consulting Ltd, Stevenage, UK
Veronique Birault
9Translation, The Francis Crick Institute, London, UK
Venizelos Papayannopoulos
4Antimicrobial Defence lab, The Francis Crick Institute, London, UK
Data Availability
All data produced in the present work are contained in the manuscript
Posted January 17, 2024.
Anti-inflammatory therapy with nebulised dornase alfa for severe COVID-19 pneumonia
Joanna C. Porter, Jamie Inshaw, Vincente Joel Solis, Emma Denneny, Rebecca Evans, Mia I. Temkin, Nathalia De Vasconcelos, Iker Valle Aramburu, Dennis Hoving, Donna Basire, Tracey Crissell, Jesusa Guinto, Alison Webb, Hanif Esmail, Victoria Johnston, Anna Last, Thomas Rampling, Elisa Theresa Helbig, Lena Lippert, Florian Kurth, Bryan Williams, Aiden Flynn, Pauline T Lukey, Veronique Birault, Venizelos Papayannopoulos
medRxiv 2022.04.14.22272888; doi: https://doi.org/10.1101/2022.04.14.22272888
Anti-inflammatory therapy with nebulised dornase alfa for severe COVID-19 pneumonia
Joanna C. Porter, Jamie Inshaw, Vincente Joel Solis, Emma Denneny, Rebecca Evans, Mia I. Temkin, Nathalia De Vasconcelos, Iker Valle Aramburu, Dennis Hoving, Donna Basire, Tracey Crissell, Jesusa Guinto, Alison Webb, Hanif Esmail, Victoria Johnston, Anna Last, Thomas Rampling, Elisa Theresa Helbig, Lena Lippert, Florian Kurth, Bryan Williams, Aiden Flynn, Pauline T Lukey, Veronique Birault, Venizelos Papayannopoulos
medRxiv 2022.04.14.22272888; doi: https://doi.org/10.1101/2022.04.14.22272888
Subject Area
Subject Areas
- Addiction Medicine (383)
- Allergy and Immunology (699)
- Anesthesia (192)
- Cardiovascular Medicine (2853)
- Dermatology (244)
- Emergency Medicine (430)
- Epidemiology (12560)
- Forensic Medicine (10)
- Gastroenterology (806)
- Genetic and Genomic Medicine (4434)
- Geriatric Medicine (401)
- Health Economics (716)
- Health Informatics (2850)
- Health Policy (1048)
- Hematology (375)
- HIV/AIDS (893)
- Medical Education (413)
- Medical Ethics (114)
- Nephrology (462)
- Neurology (4194)
- Nursing (222)
- Nutrition (617)
- Oncology (2204)
- Ophthalmology (624)
- Orthopedics (254)
- Otolaryngology (318)
- Pain Medicine (268)
- Palliative Medicine (82)
- Pathology (486)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6782)
- Radiology and Imaging (1490)
- Respiratory Medicine (900)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (201)
- Urology (174)